What is the minimum level of cognitive symptoms that would prompt you to pursue biomarker testing required for anti-amyloid therapies for Alzheimer's?
Answer from: at Academic Institution
I would require a clear diagnosis of MCI as defined by evidence of clearly impaired cognition on a valid neuropsychological test battery. I would not accept a patient based on a low-ish score on a single brief measure such as MMSE or MOCA as those tests ultimately lack specificity (as well as sensit...
Comments
at University of Minnesota As always, I agree with Dr. @Knopman.
All patients with mild cognitive impairment (MCI) should be offered biomarker testing to determine if they are eligible for anti-amyloid therapies. In-office tests such as MoCA and MMSE are sufficient to screen for MCI.
Comments
at University of Minnesota Why would we test when the side-effects are signif...
I offer amyloid biomarker testing in patients with MCI only if they qualify for amyloid therapies, if there is a genuine uncertainty about their diagnosis, and if having the biomarkers would change their management. I establish a diagnosis of MCI through clinical assessment and bedside cognitive ass...
As always, I agree with Dr. @Knopman.